CORONA REMEDIES LIMITED (CORONA) financials

CORONA REMEDIES LIMITED (CORONA) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.[1]

Market Cap: ₹12,293Cr.
Current Price: ₹2,010
Stock P/E: 58.1
ROE: 29.5%
ROCE: 33.3%
Book Value: ₹122
Dividend Yield: 0.50%
52W High / Low: ₹2,292/1,337

In Jun 2026, CORONA REMEDIES LIMITED (CORONA) reported sales ₹422 Cr and net profit ₹60 Cr.

Annual TTM: sales ₹1,479 Cr, net profit ₹199 Cr.

Shareholding: Promoters 69.00% (Sep 2026), FIIs 4.21% (Sep 2026), DIIs 16.44% (Sep 2026), Public 10.35% (Sep 2026), No. of Shareholders 21,098% (Sep 2026).

CORONA quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	314	298	294	347	361	342	353	422
Expenses	247	228	239	277	283	259	291	329
Operating Profit	67	69	54	70	78	83	62	93
OPM %	21%	23%	18%	20%	22%	24%	18%	22%
Other Income	2	1	1	2	2	-17	4	3
Interest	3	2	2	2	2	2	1	3
Depreciation	9	10	10	9	9	9	10	13
Profit before tax	57	58	43	61	70	55	54	80
Tax %	25%	23%	28%	24%	25%	25%	17%	25%
Net Profit	43	45	31	46	52	41	45	60
EPS in Rs	7.03	7.32	5.12	7.59	8.53	6.74	7.37	9.83
Raw PDF	—	—	—	—	—	—	—	—

CORONA profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	601	576	617	884	1,014	1,196	1,403	1,479
Expenses	509	471	600	756	859	956	1,109	1,162
Operating Profit	93	105	18	128	156	241	294	317
OPM %	15%	18%	2.9%	14%	15%	20%	21%	21%
Other Income	3	5	7	7	5	5	-9	-7
Interest	2	2	5	4	14	11	7	8
Depreciation	16	16	20	20	28	37	38	42
Profit before tax	77	92	-1	111	118	198	240	260
Tax %	24%	24%	-49%	23%	24%	25%	23%	—
Net Profit	59	70	-0	85	90	149	185	199
EPS in Rs	11.51	13.69	-0.08	13.85	14.80	24.37	30.22	32.47
Dividend Payout %	0%	0%	0%	20%	25%	30%	33%	—

CORONA balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	5	5	5	51	61	61	61	61
Reserves	204	263	333	270	347	419	545	685
Borrowings	13	47	50	34	28	159	86	165
Other Liabilities	71	94	144	157	159	191	237	293
Total Liabilities	293	408	532	511	595	830	929	1,204
Fixed Assets	80	81	164	162	185	384	370	554
CWIP	4	42	0	14	65	121	186	143
Investments	9	7	37	14	31	25	25	25
Other Assets	200	278	330	321	314	301	348	482
Total Assets	293	408	532	511	595	830	929	1,204

CORONA cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	19	43	79	98	103	157	190	229
Cash from Investing Activity	-23	-50	-102	-66	-50	-267	-84	-256
Cash from Financing Activity	4	30	0	-30	-45	99	-107	25
Net Cash Flow	-1	23	-23	2	8	-11	0	-1
Free Cash Flow	19	1	6	64	9	-129	99	56
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	49%	65%	101%	557%	100%	112%	97%	95%

CORONA shareholding pattern (%)
Category	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	69.00%	69.00%	69.00%	69.00%
FIIs	1.84%	2.25%	3.63%	4.21%
DIIs	6.77%	7.02%	12.90%	16.44%
Public	22.41%	21.75%	14.47%	10.35%
No. of Shareholders	31,035	19,609	20,185	21,098

CORONA key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	95	105	131	44	36	36	36	38
Inventory Days	69	52	77	184	182	158	200	175
Days Payable	126	110	182	211	163	184	221	206
Cash Conversion Cycle	38	48	27	17	55	10	14	7
Working Capital Days	67	81	86	16	30	-2	9	-15
ROCE %	—	30%	27%	1%	29%	25%	31%	33%

CORONAUpdated 21 Oct 2026, 5:18

Corona Remedies Limited

CORONAUpdated 21 Oct 2026, 5:18

Market Cap

₹12,293Cr.

Current Price

₹2,010

High / Low

₹2,292/1,337

Stock P/E

58.1

ROE29.5%

ROCE33.3%

Book Value₹122

Face Value₹10.0

Dividend Yield0.50%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Sep 2024	314	3	247	2	9	57	25	43	7.03
Dec 2024	298	2	228	1	10	58	23	45	7.32
Mar 2025	294	2	239	1	10	43	28	31	5.12
Jun 2025	347	2	277	2	9	61	24	46	7.59
Sep 2025	361	2	283	2	9	70	25	52	8.53
Dec 2025	342	2	259	-17	9	55	25	41	6.74
Mar 2026	353	1	291	4	10	54	17	45	7.37
Jun 2026	422	3	329	3	13	80	25	60	9.83

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2019	509	1	444	3	14	54	35	35	6.8
Mar 2020	601	2	509	3	16	77	24	59	11.51
Mar 2021	576	2	471	5	16	92	24	70	13.69
Mar 2022	617	5	600	7	20	-1	-49	0	-0.08
Mar 2023	884	4	756	7	20	111	23	85	13.85
Mar 2024	1014	14	859	5	28	118	24	90	14.8
Mar 2025	1196	11	956	5	37	198	25	149	24.37
Mar 2026	1403	7	1109	-9	38	240	23	185	30.22
TTM	1479	8	1162	-7	42	260	—	199	32.47

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	69%
FIIs	4.21%
DIIs	16.44%
Public	10.35%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2025	69%	1.84%	6.77%	22.41%
Mar 2026	69%	2.25%	7.02%	21.75%
Jun 2026	69%	3.63%	12.9%	14.47%
Sep 2026	69%	4.21%	16.44%	10.35%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2019	5	204	13	71	293	80	4	9	200	293
Mar 2020	5	263	47	94	408	81	42	7	278	408
Mar 2021	5	333	50	144	532	164	0	37	330	532
Mar 2022	51	270	34	157	511	162	14	14	321	511
Mar 2023	61	347	28	159	595	185	65	31	314	595
Mar 2024	61	419	159	191	830	384	121	25	301	830
Mar 2025	61	545	86	237	929	370	186	25	348	929
Mar 2026	61	685	165	293	1204	554	143	25	482	1204

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2019	19	-23	4	-1
Mar 2020	43	-50	30	23
Mar 2021	79	-102	0	-23
Mar 2022	98	-66	-30	2
Mar 2023	103	-50	-45	8
Mar 2024	157	-267	99	-11
Mar 2025	190	-84	-107	0
Mar 2026	229	-256	25	-1

Key ratios

Historical financial ratios

Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	95	105	131	44	36	36	36	38
Inventory Days	69	52	77	184	182	158	200	175
Days Payable	126	110	182	211	163	184	221	206
Cash Conversion Cycle	38	48	27	17	55	10	14	7
Working Capital Days	67	81	86	16	30	-2	9	-15
ROCE %	—	30%	27%	1%	29%	25%	31%	33%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of CORONA REMEDIES LIMITED (CORONA)?

The reported market capitalisation for CORONA REMEDIES LIMITED (CORONA) is ₹12,293Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of CORONA?

The current price shown for CORONA REMEDIES LIMITED (CORONA) on Fincrux is ₹2,010 with a 52-week high/low of ₹2,292/1,337.

What is the P/E ratio of CORONA REMEDIES LIMITED (CORONA)?

The stock P/E for CORONA REMEDIES LIMITED (CORONA) is 58.1 on Fincrux, with ROE at 29.5% and ROCE at 33.3%.

What were CORONA latest quarterly results?

For Jun 2026, CORONA REMEDIES LIMITED (CORONA) reported sales ₹422 Cr and net profit ₹60 Cr (figures in ₹ crore unless noted).

What are CORONA annual sales and net profit?

For TTM, CORONA REMEDIES LIMITED (CORONA) shows sales of ₹1,479 Cr and net profit of ₹199 Cr on the Fincrux profit & loss statement.

Who owns CORONA REMEDIES LIMITED (CORONA)?

Latest shareholding for CORONA REMEDIES LIMITED (CORONA) on Fincrux: Promoters 69.00% (Sep 2026), FIIs 4.21% (Sep 2026), DIIs 16.44% (Sep 2026), Public 10.35% (Sep 2026), No. of Shareholders 21,098% (Sep 2026).

Where can I find CORONA REMEDIES LIMITED (CORONA) financials?

CORONA REMEDIES LIMITED (CORONA) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show CORONA balance sheet and cash flow?

Yes. The CORONA REMEDIES LIMITED (CORONA) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 21 October 2026 at 5:18